Operating margin · 2018–2025
Royalty Pharma operating margin
65.6%+14.8% · FY2025
Royalty Pharma (RPRX) reported 65.6% in operating margin for fiscal 2025, +14.8% year on year.
| Fiscal year | Operating margin | Change | Filing |
|---|---|---|---|
| FY2025 | 65.6% | +14.8% | Derived |
| FY2024 | 57.1% | −9.9% | Derived |
| FY2023 | 63.4% | +361.7% | Derived |
| FY2022 | 13.7% | −78.0% | Derived |
| FY2021 | 62.5% | −16.9% | Derived |
| FY2020 | 75.2% | −48.0% | Derived |
| FY2019 | 144.6% | +90.2% | Derived |
| FY2018 | 76.0% | — | Derived |
Operating margin — Operating margin is operating income divided by revenue. Only companies with at least $1 billion in revenue are ranked here.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2018–2025 compound annual growth −2.1%
Calculated from two reported figures, so it has no single filing of its own.
Operating margin at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Royalty Pharma operating margin |url=https://companiesranked.com/en/company/royalty-pharma/operating-margin |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Royalty Pharma operating margin. CompaniesRanked. https://companiesranked.com/en/company/royalty-pharma/operating-marginBibTeX
@misc{companiesranked-en-company-royalty-pharma-operating-margin-2026,
author = {{CompaniesRanked}},
title = {{Royalty Pharma operating margin}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/royalty-pharma/operating-margin}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.